<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238066</url>
  </required_header>
  <id_info>
    <org_study_id>Prostata-BT-HT</org_study_id>
    <nct_id>NCT03238066</nct_id>
  </id_info>
  <brief_title>Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy</brief_title>
  <acronym>Prostata-BT-HT</acronym>
  <official_title>A Prospective Phase II Study of Salvage Brachytherapy in Combination With Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following External Beam Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent&#xD;
      prostate carcinoma following external beam radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent&#xD;
      prostate carcinoma following external beam radiation therapy:&#xD;
&#xD;
      Salvage brachytherapy: HDRBT: 3 x 10 Gy specified on prostate capsule/tumor margin (d1, 22,&#xD;
      43) or PDRBT: 2 x 30 Gy specified on prostate capsule/tumor margin (d1-3, 29-31)&#xD;
      Hyperthermia: prostate heated to 40 - 47˚C for 30-60 minutes (60 minutes recommended) prior&#xD;
      to brachytherapy dose delivery. Maximum temperature in surrounding critical normal organs&#xD;
      should not exceed 43˚C&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of late GI/GU grade 3 and more toxicities</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute GI/GU treatment-related adverse events</measure>
    <time_frame>up to 24 months after start of recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical failure</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
    <description>defined rise of PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical patterns of tumor recurrence</measure>
    <time_frame>up to 60 Months in Follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physician can choose either HDR or PDR brachytherapy.&#xD;
If HDR BT is chosen:&#xD;
d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT&#xD;
If PDR BT is chosen:&#xD;
d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>HDR/PDR brachytherapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperthermia</intervention_name>
    <description>Interstitial hyperthermia</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed locally recurrent prostate cancer - biopsy performed &lt; 6&#xD;
             months before registration;&#xD;
&#xD;
          -  Histology: Adenocarcinoma, every Gleason score (2-10)&#xD;
&#xD;
          -  Initial treatment (EBRT) completed &gt; 24 months prior to biopsy;&#xD;
&#xD;
          -  Androgen deprivation therapy for prostate cancer should be discontinued at least 3&#xD;
             months prior to patient registration&#xD;
&#xD;
          -  Staging performed within 12 weeks prior to registration:&#xD;
&#xD;
               -  Local stage evaluated by DRE, TRUS or - if necessary - mpMRI (T1b, T1c, T2a, T2b,&#xD;
                  T2c, T3a, T3b);&#xD;
&#xD;
               -  Negative lymph nodes by imaging studies (at least one of these: choline PET scan,&#xD;
                  pelvic ± abdominal CT or MRI) or by lymphadenectomy (cN0 or pN0);&#xD;
&#xD;
               -  Negative bone scan (M0);&#xD;
&#xD;
          -  PSA-DT &gt; 6 months (PSA measurements taken of the 12 months prior to registration)&#xD;
&#xD;
          -  Zubrod Performance Scale 0-2 (Appendix V) International Prostate Symptoms Score (IPSS)&#xD;
             &lt; 20 (Appendix VI), the IPSS score can be evaluated in patient on alpha-blockers;&#xD;
&#xD;
          -  Baseline gastrointestinal (GI) or genitourinary (GU) toxicity grade 0-1 as defined in&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
&#xD;
        In TRUS volume study performed 0-4 weeks before registration patient meets eligibility&#xD;
        criteria for prostate brachytherapy as follows:&#xD;
&#xD;
          -  Prostate/tumor volume &lt;60ml&#xD;
&#xD;
          -  The distance rear prostate edge - rectal mucosa &gt;5mm&#xD;
&#xD;
          -  Interference of pubic arch ruled out&#xD;
&#xD;
          -  If local stage T3b: it must be possible to cover by the brachytherapy dose cancer&#xD;
             infiltration&#xD;
&#xD;
               -  Prostate lenght (from apex plane to base plane) ≤ 45mm (technical criterion for&#xD;
                  915 MHz frequency antennas)&#xD;
&#xD;
               -  The patient is suitable for spinal or general anesthesia&#xD;
&#xD;
               -  Age &gt; 18 y.&#xD;
&#xD;
               -  Life expectancy &gt; 5 years&#xD;
&#xD;
               -  absence of any psychological, familial, sociological or geographical condition&#xD;
                  potentially hampering compliance with the study protocol and follow-up schedule;&#xD;
                  those conditions should be discussed with the patient before registration in the&#xD;
                  trial&#xD;
&#xD;
               -  The patient must sign a study-specific informed consent form before study&#xD;
                  registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe, active comorbidities:&#xD;
&#xD;
               -  Decompensated congestive heart disease&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation, respiratory failure&#xD;
&#xD;
               -  Hepatic insufficiency resulting in coagulation defects or clinical jaundice&#xD;
&#xD;
          -  Other active malignancy or treatment of invasive or hematological malignancy&#xD;
&#xD;
          -  Evidence of extraprostatic disease at local recurrence:&#xD;
&#xD;
               -  Local stage T4&#xD;
&#xD;
               -  Histologic or radiologic evidence of lymph node metastases (N1 or pN1)&#xD;
&#xD;
               -  Presence of distant metastases (M1)&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  TURP within 6 months prior to registration&#xD;
&#xD;
               -  Prostatic salvage cryosurgery performed at least 6 months before registration&#xD;
&#xD;
               -  HIFU performed at least 6 months before registration&#xD;
&#xD;
               -  Androgen deprivation therapy within 3 months prior to registration&#xD;
&#xD;
          -  Baseline gastrointestinal (GI) or genitourinary (GU) toxicity grade ≥ 2 as defined in&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vratislav Strnad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Medical Director of the Dept. of Radiooncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vratislav Strnad, MD</last_name>
    <phone>++49(0)9131-85</phone>
    <phone_ext>33419</phone_ext>
    <email>vratislav.strnad@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Studiensekretariat</last_name>
    <phone>++49(0)9131-85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Strahlenklinik im Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vratislav Strnad, MD</last_name>
      <phone>++49(0)9131-85</phone>
      <phone_ext>33419</phone_ext>
      <email>vratislav.strnad@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Radiotherapii</name>
      <address>
        <city>Kraków</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Kukielka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Institute - Oncology Center</name>
      <address>
        <city>Warszaw</city>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateusz Dabkowski, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>Vratislav Strnad</investigator_full_name>
    <investigator_title>Assistant Medical Director of the Dept. of Radiooncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

